Evaluation of the Effectiveness and Safety of Immunosuppressive and Biological Therapy of Atopic Dermatitis in Childhood

1. Age over 6 years inclusive;
2. Atopic dermatitis diagnosed at least 12 months before the start of the study;
3. Atopic dermatitis of moderate or severe course;

4. Consent to discontinue the use of the following prohibited drugs or any of the following therapies at least 4 weeks before the start of the study and not to use them throughout the study, unless otherwise specified below:

   1. Oral systemic corticosteroids;
   2. Other systemic immunosuppressive drugs;
   3. Phototherapy, including therapeutic phototherapy (psoralen plus ultraviolet A, ultraviolet B), excimer laser, and self-medication using a tanning bed;
5. A signed and dated informed consent received from the patient's parents (guardians), as well as from a patient over 14 years of age, to participate in the study.
6. Ability to attend control visits within the specified time frame

Exclusion Criteria:

1. Use of other genetically engineered biological preparations in therapy;
2. Participation in other clinical trials;
3. The presence of other concomitant skin diseases in the present or in the past, which could affect the assessment of the effect of the study drugs on the course of atopic dermatitis;
4. The presence of herpetic eczema within 12 months before the start of the study;
5. A history of two or more cases of herpetic eczema;
6. The presence in the present of a skin infection for which is required or is being treated with antibiotics for topical use or systemic antibiotics;

7. Therapy with the following drugs:

   1. Other genetically engineered biological preparations less than 5 half-lives before the start of the study.
   2. Any corticosteroid for oral and parenteral administration and administration, which were in therapy for 2 weeks before enrollment in the study, or the possible need for parenteral injection of corticosteroids during the course of the study.
   3. Intra-articular corticosteroid injection within 2 weeks prior to study enrollment; Note: The use of intranasal or inhaled steroids is permitted throughout the study.
8. Extensive or complete disability, significantly limiting personal care or determining the inability to carry it out.
9. Immunodeficiency disease;
10. The presence in the past or present of any serious and / or unstable disease, which, in the opinion of the investigator, may pose an unacceptable risk to the patient in the case of the use of the investigational drug or interfere with the interpretation of the data;
11. History of lymphoproliferative disease; or manifestations or symptoms suggesting the possible presence of lymphoproliferative disease, including lymphadenopathy or splenomegaly; either primary or recurrent malignant disease in active form; or remission after a clinically significant malignant disease lasting less than 5 years;
12. The course of a viral, bacterial, fungal or parasitic infection;
13. Failure or unwillingness of the patient or patient's parent / caregiver / patient legal guardian to comply with the requirements of research participants throughout the study and / or unwillingness to follow research restrictions / procedures, including the use of data loggers.
14. Contraindications to the use of adrenaline.